The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling
Authors:
- 24 March 2014
- journal article
- Published by Springer Nature in Oncogene
- Vol. 34 (9) , 1105-1115
Abstract
HER3/ErbB3, a member of the epidermal growth factor receptor (EGFR) family, has a pivotal role in cancer and is emerging as a therapeutic antibody target. In this study, we identified NEDD4 (neural precursor cell expressed, developmentally downregulated 4) as a novel interaction partner and ubiquitin E3 ligase of human HER3. Using molecular and biochemical approaches, we demonstrated that the C-terminal tail of HER3 interacted with the WW domains of NEDD4 and the interaction was independent of neuregulin-1. Short hairpin RNA knockdown of NEDD4 elevated HER3 levels and resulted in increased HER3 signaling and cancer cell proliferation in vitro and in vivo. A similar inverse relationship between HER3 and NEDD4 levels was observed in prostate cancer tumor tissues. More importantly, the upregulated HER3 expression by NEDD4 knockdown sensitized cancer cells for growth inhibition by an anti-HER3 antibody. Taken together, our results suggest that low NEDD4 levels may predict activation of HER3 signaling and efficacies of anti-HER3 antibody therapies.Keywords
This publication has 60 references indexed in Scilit:
- ERBB3 (HER3) is a key sensor in the regulation of ERBB‐mediated signaling in both low and high ERBB2 (HER2) expressing cancer cellsCancer Medicine, 2012
- Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancerBritish Journal of Cancer, 2012
- Nedd4‐1 binds and ubiquitylates activated FGFR1 to control its endocytosis and functionThe EMBO Journal, 2011
- Structure of the HECT:ubiquitin complex and its role in ubiquitin chain elongationEMBO Reports, 2011
- E3 ubiquitin ligases in ErbB receptor quantity controlSeminars in Cell & Developmental Biology, 2010
- Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4‐2 using proteome arraysMolecular Systems Biology, 2009
- The ERBB3 receptor in cancer and cancer gene therapyCancer Gene Therapy, 2008
- Expression of the HER1–4 family of receptor tyrosine kinases in breast cancerThe Journal of Pathology, 2003
- The ErbB receptors and their role in cancer progressionExperimental Cell Research, 2003
- Mdm2 promotes the rapid degradation of p53Nature, 1997